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Abstract  
 
Breast carcinoma (BC) corresponds to 23 % of all cancers in women, with 1.38 million new cases and 
460,000 deaths worldwide annually. Despite the significant advances in the identification of molecular 
markers and different modalities of treatment for primary BC, the ability to predict its metastatic behavior is 
still limited. The purpose of this study was to identify novel molecular markers associated with distinct 
clinical outcomes in a Brazilian cohort of BC patients. We generated global gene expression profiles using 
tumor samples from 24 patients with invasive ductal BC who were followed for at least 5 years, including a 
group of 15 patients with favorable outcomes and another with nine patients who developed metastasis. We 
identified a set of 58 differentially expressed genes (p ≤ 0.01) between the two groups. The prognostic value 
of this metastasis signature was corroborated by its ability to stratify independent BC patient datasets 
according to disease-free survival and overall survival. The upregulation of B3GNT7, PPM1D, TNKS2, PHB, 
and GTSE1 in patients with poor outcomes was confirmed by quantitative reverse transcription polymerase 
chain reaction (RT-qPCR) in an independent sample of patients with BC (47 with good outcomes and eight 
that presented metastasis). The expression of BCL2-associated agonist of cell death (BAD) protein was 
determined in 1276 BC tissue samples by immunohistochemistry and was consistent with the reduced BAD 
mRNA expression levels in metastatic cases, as observed in the oligoarray data. These findings point to 
novel prognostic markers that can distinguish breast carcinomas with metastatic potential from those with 
favorable outcomes. 
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Introduction 
Breast cancer (BC) is a complex and heterogeneous disease, with distinct clinical presentations in different 
patient and ethnic populations. Even patients affected by tumors with similar histomorphological 
appearances may present divergent clinical courses [1, 2]. During the last few decades, several clinical and 
pathological indicators, such as histological grade, tumor size, and lymph node involvement, have been used 
for prognostic prediction in breast cancer patients [3]. In addition, the predictive and prognostic markers 
applied to the management of patients include the estrogen (ESR1) and progesterone receptor (PR) statuses 
and human epidermal growth factor receptor 2 (Her2) amplification and/or overexpression. The clinico-
pathological risk assessment is routinely based on these factors and is used to guide decisions on adjuvant 
systemic treatment [4]. Despite the improvements in risk stratification, the current prognostic factors show 
moderate accuracy in classifying breast tumors according to their clinical behaviors. It is still a clinical 
challenge to identify the patients who are at a low risk of relapse and have been submitted to overtreatment 
after optimal locoregional treatment as well as those who are at a high risk of relapse and would benefit from 
a more aggressive adjuvant systemic therapy and closer follow- up. 
New biomarker development is required to assist clinicians in BC detection and diagnosis, risk stratification, 
disease subtyping, prediction of treatment responses, and surveillance, allowing personalized cancer 
management. The integration between novel biomarkers and routinely tested clinico-pathological features, 
such as hormone receptor (HR) and Her2 statuses, may guide clinicians in their systemic therapy decisions 
regarding both primary and metastatic tumors [5–8]. 
In recent years, gene expression prognostic tests for BC that are better predictors of clinical outcomes than 
traditional pathological factors have been developed [9–12]. One of the first commercially available and US 
Food and Drug Administration (FDA)-approved signatures was the 70-gene MammaPrint assay® (Agendia 
Inc.). MammaPrint is among the most validated multigene prognostic signatures and is widely used to 
stratify lymph node-negative patients as having low or high risks of distant metastases at 5 years from 
surgery [13]. The 21-gene Oncotype Dx® assay (Genomic Health Inc.) has also been extensively used to 
estimate the risk of relapse in estrogen receptor (ER)+, node-negative BC, and their chemosensitivities. A 
common feature between both signatures is the ability to better estimate the risk of recurrence compared to 
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conventional clinical criteria, such as the St. Gallen and NIH consensus criteria or web-based decision tools 
(e.g., Adjuvant! Online; https://www.adjuvantonline.com). This improvement in risk estimation can help to 
reduce the number of over treated women, which emphasizes the advantage of these gene signatures over the 
clinical guidelines [14, 15]. Other multigene expression-based prognostic tests interrogating different sets of 
genes have been made commercially available more recently, with comparable prognostic performances in 
BC [8]. PAM50, which is based on a 50-gene set, generates a numerical score (risk of recurrence, or ROR) 
that, along with the clinical features, estimates the risk of relapse at 10 years in postmenopausal women with 
stage I/II node-negative or stage II node-positive (one to three positive lymph nodes) and HR-positive BC 
[16]. The 97-gene MapQuant Dx® (Ipsogen-Qiagen) has been used to resolve intermediate grade 2 BC 
tumors into those with a good prognosis, grade 1-like behavior, or more aggressive grade 3-like tumors [17]. 
Finally, the breast cancer index (BCI; Biotheranostics, Inc.) combines the information from the expression 
ratio of two estrogen-regulated genes (HOXB13 :IL17BR) with the expression profile of five other genes 
known as the molecular grade index (MGI) to estimate the individualized risk of the late distant recurrence 
of breast cancer [18]. 
These so-called first generation multigene prognostic signatures [19] show little overlap in their gene lists, 
which indicates that the results from the studies are unstable [20, 21]. In fact, a single dataset may generate 
several different signatures with clinically relevant subgroups of breast cancer [22]. On the other hand, 
comparative studies and meta-analyses have demonstrated that BC prognostic gene signatures tend to have 
similar performances and show relatively good concordance with their prognostic ability to identify patients 
with worse prognoses [23–27] and could provide a refined estimate of disease-free survival, with added 
value beyond the current clinical indicators [28]. Despite their demonstrated efficacy, the lack of consensus 
and low overlap across the genes identified in these studies indicate that the potential for identifying novel 
genes and expression signatures that are correlated with patient outcomes in BC has not been fully exploited. 
To our knowledge, there are no descriptive studies of the molecular signatures of breast carcinomas from 
Brazilian patients. Brazilians form one of the most heterogeneous populations in the world, as a result of five 
centuries of interethnic crosses between people from three continents. For this reason, the molecular 
signatures of breast carcinomas from Brazilian patients may lead to the identification of new molecular 
markers that are common among several ethnicities. Thus, the purpose of this study was to identify new 
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molecular markers of BC that are common in the Brazilian population and determine whether these genes 
can predict the patients’ clinical outcomes. Global gene expression profiles generated from 24 locally 
invasive ductal breast carcinoma samples from patients staged M0 at diagnosis with subsequent metastasis (n 
= 9) and patients who remained disease-free at a minimum follow-up of 60 months (n = 15) were used to 
identify a 58-gene set associated with patient outcome. The robustness of this signature to predict disease 
outcome (disease-free survival and overall survival) was corroborated by the analysis of publicly available 
BC gene expression datasets. Quantitative reverse transcription polymerase chain reaction (RT-qPCR) was 
used to confirm the differential expression of a selected set of candidate markers in an independent 
validation set of 55 new cases (comprising 47 patients with 5-year metastasis-free BC and eight patients with 
metastatic disease). Furthermore, the potential of the BCL-2-associated agonist of cell death promoter (BAD) 
protein as a new prognostic biomarker of BC was validated using a tissue microarray comprising 1276 BC 
samples. 
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Material and Methods 
Patients  
The study comprised 79 female patients with infiltrating ductal breast cancer with a mean age of 58±16 years 
(ranged from 24-94 years). The mean follow-up after the surgery was 87.5 ± 17.4 months (ranged from 57 to 
117 months). The criteria for patient inclusion were no previous or concomitant diagnosis of any cancer or 
metastasis at diagnosis. Patients were treated with segmental resection or mastectomy, including dissection 
of the axillary lymph nodes, followed by radiotherapy and adjuvant systemic therapy, if indicated. None of 
them received radiotherapy or chemotherapy prior to surgery. After surgery, 64 patients (81%) received 
radiotherapy and 43 (54%) were treated for 60 months with tamoxifen (20 mg/day) at the end of 
chemotherapy. All patients that developed metastasis (17 cases) presented operable stage II and III breast 
cancers, with larger tumors (> 2 cm) often poorly differentiated, and all except one showed positive axillary 
lymph nodes. Of this group, the majority (13 patients) received chemotherapy following surgery. From 14 
patients with positive ER status, the majority (11 patients) was also treated with hormone therapy. 
Fresh tissue samples were macro-dissected (>80% of tumor cells) and used for RNA isolation and 
subsequent gene expression analysis. Thirty-eight cases were used for global gene expression analysis using 
oligoarrays and 55 cases used for qRT-PCR analysis of candidate genes. In addition, tumor tissue samples 
from 1,276 ductal breast carcinomas were evaluated for protein expression with immunohistochemistry. The 
samples were obtained from Amaral Carvalho Hospital, Jau (SP, Brazil) and AC Camargo Cancer Center 
(SP-Brazil). Written informed consent from all patients was obtained during the collect period, and the study 
was reviewed and approved by the Ethics Committees from both Institutions (CEP FHAC 340/04 and CEP 
ACCC 1155/08).  
 
Analysis design 
The expression profiles from tumor samples obtained from 38 patients were used to identify the molecular 
signatures that were correlated with the Her2 and Ki67 expression statuses, two of the currently used 
prognostic markers. The detailed clinico-pathological data from these patients is shown in Supplementary 
Table 1. A subset of 24 cases (test set) with known outcomes was used to identify a gene expression 
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signature associated with the development of metastasis. The ability of the “metastasis signature” to stratify 
patients based on the time to develop metastasis was compared to a combined prognostic score based on 
traditional clinico-pathological criteria that assigned patients to a “good outcome” group comprised of 15 
patients who remained free of disease at least 5 years after surgery. Nine patients who developed metastasis 
were assigned to the “poor outcome” group. The criteria used to assign a patient to the good outcome group 
were the presence of at least five of the following parameters: (i) tumor clinical stage I or IIA; (ii) tumor size 
less than 2 cm; (iii) histopathological grade I or II; (iv) negative axillary lymph node status or less than four 
nodes compromised; (v) ER- positive (scores 2+/3+) in the immunohistochemistry assay; (vi) Her2-negative 
or (1+) in the immunohistochemistry assay; and (vii) low proliferation index (<25 % of cells with Ki67-
positive staining). To verify if the development of metastasis in this sample set could be explained by the 
traditional clinico-pathological factors alone, the association between these variables was evaluated using 
Fisher’s exact test (GraphPad Prism Statistical Software version 5.0, San Diego, CA, USA) and statistical 
significance was designated at p ≤ 0.05 (Supplementary Table 2). The histological grade, proliferation index, 
and adjuvant chemotherapy were individual characteristics that were statistically related to the development 
of metastasis in the group of patients analyzed. 
The independent validation set (55 samples) included 47 samples from patients with good outcomes and 
eight samples from patients with poor outcomes. A summary of the clinico-pathological data from the 79 
patients with a known follow-up that comprised the samples used in the gene expression experiments (test + 
validation set) is shown in Supplementary Table 3. Information on the additional 1276 cases used in tissue 
microarray validation experiments is provided in Supplementary Table 4. 
 
RNA isolation and global gene expression analysis 
The total RNA was extracted using the RNeasy mini Kit (Qiagen GmbH, Germany). RNA samples were 
treated with DNAse I Amplification Grade (Life Technologies, Rockville, MD, USA) according to the 
manufacturer’s recommendations. The quantification and integrity assessment of RNA samples were 
performed using the ND-1000 spectrophotometer (NanoDrop Inc.) and Agilent 2100 Bioanalyzer (Agilent 
Technologies), respectively. Only samples with RIN (RNA integrity number) ≥ 7 were considered further. 
Gene expression profiles were collected using Whole Human Genome CodeLink bioarrays (GE Healthcare 
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Buckinghamshire, UK) that interrogate approximately 54,000 transcripts (GEO accession GPL11010). In 
brief, first-strand cDNA was produced using 2 µg of total RNA from each sample, Superscript II reverse 
transcriptase, and a T7-poly-dT primer. Second-strand cDNA was produced using RNase H and E. coli 
DNA polymerase I. Double-stranded cDNA was column purified (QIAquick, Qiagen) and biotin-labeled 
cRNA targets were generated by an in vitro transcription reaction using T7 RNA polymerase and biotin-11-
UTP (Perkin Elmer-Foster City, CA, USA). Fragmented cRNA from each sample was hybridized to 
CodeLink microarrays overnight at 37 °C in a shaking incubator at 300 rpm. After post-hybridization 
washes, hybridized targets were revealed by incubating the arrays with a Cy5-Streptavidin conjugate. All 
reagents used for the synthesis and fragmentation of cRNA were provided in the CodeLink expression assay 
kit (GE Healthcare). Signal of the Cy5-dye from hybridized targets were detected with an arrayWoRx 
Biochip Reader (Applied Precision LLC, Issaquah, WA, USA). CodeLink Expression Analysis software 
(GE Healthcare) was used to extract background-subtracted spot intensities from microarray images. A set 
of 23,566 probes that showed valid measurements in at least 60% of the samples was further analyzed. 
Intensity data were normalized across samples using the quantile method [29]. Raw and normalized 
expression measurements are deposited at the Gene Expression Omnibus (GEO) under accession number 
GSE73383. 
A Signal-to-Noise Ratio (SNR) statistical test [30] was used to identify gene expression signatures correlated 
with pathological and clinical parameters of samples. The statistical significance of the differential 
expression (p-values) was ascertained by bootstrap (1,000 random permutations). Expression profiles of 
transcripts selected in each analysis were clustered hierarchically (UPGMA with Euclidean distance) and 
visualized using the Spotfire Decision Site software (TIBCO Spotfire, Somerville, MA, USA). The 
robustness of the gene expression signature of metastasis was evaluated by leave-one-out resampling [11] 
considering a p ≤ 0.01 cutoff. 
 
Reverse Transcription Quantitative Polymerase Chain Reaction (qRT-PCR) 
Real time quantitative RT-PCR amplifications for a subset of genes selected from the metastasis signature 
(B3GNT7, PPM1D, TNKS2, PHB, and GTSE1 genes) were performed in duplicate on an ABI Prism 7000 
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Sequence Detection System (Applied Biosystems, Foster City, CA, USA), using Power SYBR Green I 
reagent (Applied Biosystems). These genes were chosen by their importance in cell proliferation or their 
association with biological processes related to metastasis. The primers shown in Supplementary Table 5 
were designed using the Primer Express software (v3.0; Applied Biosystems). The standard curves of the 
targets and reference genes showed similar amplification efficiencies (> 90%). The qPCR amplification data 
were analyzed using the Sequence Detection System software (v1.0; Applied Biosystems). Only replicates 
with low variability (i.e. Δ cycle quantification < 0.5) were considered for further analyses. GAPDH was 
selected as the reference gene [31]. The relative expression of target genes was calculated according to the 
ΔCt method [32].  
The normalized expression levels of target genes in the tumor samples were represented as fold-change 
relative to their abundance in a pool of non-tumor breast tissues (Relative Quantification, RQ), calculated as 
follows: 2-(∆Ct test sample - ∆Ct control sample). The statistical analysis of qRT-PCR results was performed using 
GraphPad InStat software (version 3.00). The Mann-Whitney test was used to ascertain the statistical 
significance of the expression levels evaluated by RT-qPCR. The correlation between the oligoarray and RT-
qPCR data was evaluated using Spearman’s correlation test. For this analysis, the raw expression values 
estimated by each of the two methodologies were used, and the statistical significance was ascertained using 
a p < 0.05 threshold. 
 
In silico validation and functional analysis of the metastasis signature 
The individual abilities of the genes present in the metastasis signature to classify patients according to their 
disease outcomes (presence/absence of metastasis) were evaluated by receiver operating characteristic 
(ROC) curves using GraphPad Prism 7 software (GraphPad Software, Inc.). For each gene, the ability to 
correctly identify disease-free vs. metastatic patients was evaluated by calculating the area under the ROC 
curve (AUC) using a non-parametric method. The ability of the 58 signatures to predict patient outcome as a 
multigene biomarker was tested using SurvExpress, a web-based tool that provides survival analysis and risk 
assessment publicly available cancer datasets [33]. Briefly, the tool applies the Cox proportional hazard 
regression model to generate risk scores (also called prognostic indexes) that relate patient survival (disease-
free or overall survival) to the expression of a given gene list. The high- and low-risk patient groups were 
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generated by splitting the samples at the median after ranking them by their risk scores. The log-rank test 
was used to ascertain the statistical significance of the difference be- tween the survival curves. 
Ingenuity Pathway Analysis (IPA v8.0, Ingenuity® Systems, Redwood City, CA, USA; 
http://www.ingenuity. com) was used to identify the enriched pathways and biological interaction networks 
of the differentially expressed genes identified in the oligoarray analysis. Fischer’s exact test was applied to 
identify the significant networks and pathways that were represented within the respective gene sets. In 
parallel, we searched for significantly enriched pathways among the metastasis signature with the software 
KOBAS 2.0 [34], which incorporates knowledge across 1327 species from five pathway databases (KEGG 
PATHWAY, PID, BioCyc, Reactome, and PANTHER) and five human disease databases (OMIM, KEGG 
DISEASE, FunDO, GAD, and NHGRI GWAS Catalog). Only pathways identified simultaneously by IPA 
and KOBAS with a p ≤ 0.05 were considered for further interpretation (Table 1). 
 
 
Protein Expression by Immunohistochemistry using Tissue Microarrays (TMA)  
Tissue microarrays (TMAs) with core biopsies from 1276 ductal breast carcinomas were assembled as 
previously described using a Manual Tissue Microarrayer (Beecher Instruments®, Silver Springs, USA) 
[35]. Tissue cores with a dimension of 1.0 mm from each specimen were punched and arrayed in 
quadruplicate on  recipient paraffin blocks. Paraffin-embedded breast tumor samples were sectioned (3 µm) 
and mounted on silane-coated glass slides for hematoxylin-eosin (HE) staining and immunohistochemistry 
(IHC). 
IHC was performed using the anti-BAD (clone Y208, Epitomics diluted in 1:1500, antigen retrieval in 
EDTA/Tris, pH 9.0) primary antibody and secondary antibodies (Advanced TM HRP Link, Dako 
Cytomation, K0690, Denmark). Positive (BAD, prostate tissue) and two negative controls (omitting the 
primary antibody and replacing the primary antibody with normal rabbit serum) were assessed by IHC. BAD 
expression in each sample core was scored as positive or negative following a visual inspection of the 
cytoplasmic immunostaining. The final scores (median of the four cores) were obtained based on the 
immunostaining intensity in the cytoplasm and were denominated as “negative/weak” (score 0–1) or 
“positive” (score 2–3). A chi-square test was applied to determine the association strength between the 
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categorical variables (p < 0.05). Univariate Kaplan-Meier (KM) survival curves were calculated for systemic 
disease-free survival (SDFS) and cancer-specific survival (CSS) probabilities by considering a minimum 60-
month follow-up after surgery. The log-rank test was used to assess the statistical significance of the KM 
curves. IHC analysis was blinded to the outcomes and clinical aspects of each tumor specimen. A minimum 
5-year follow-up after surgery was used for both SDFS and CSS. Multivariate analysis was performed using 
the Cox proportional hazard model. The statistical analyses were performed using MedCalc v. 15.11.0 
(MedCalc Software, Belgium), GraphPad Prism3 (San Diego, CA, USA), and SPSS version 15.0 (SPSS, 
Chicago, IL, USA). 
 
Results 
 
Gene expression signature associated with metastatic ductal breast carcinomas 
First, the global gene expression profiles were evaluated in 38 BC samples to identify gene signatures that 
were correlated with the commonly used prognostic markers of breast cancer outcome (expression of 
ESR1/PR, Ki67, and Her2), with the aim of distinguishing patients who developed metastasis from those that 
remained disease-free. Using a two-class supervised analysis based on a SNR with permutation [30], we 
identified statistically significant gene expression signatures that were correlated with the expression of 
estrogen/progesterone recep- tors (p ≤ 0.005), Ki67 (p ≤ 0.001), or Her2 (p ≤ 0.001). Although these 
expression signatures accurately discriminate samples based on each prognostic marker, they are poor 
estimators of risk of metastatic progression in patients with invasive BC (Supplementary Figure 1). 
Next, we sought to identify a gene expression signature that was correlated with disease outcome, i.e., the 
development of metastasis. For this analysis, we only included samples from the 15 patients with a good 
prognosis that remained free of disease for at the least 5 years. SNR with permutation was used and 
identified 200 full-length or partial transcript (EST) sequences that were differentially expressed (p ≤ 0.01) 
between the samples from patients who developed metastasis (nine cases) and those from patients with a 
good prognosis that remained disease-free (15 cases). Hierarchical clustering of this transcript set correctly 
grouped the samples according to their metastatic outcome, with the exception of one sample 
(Supplementary Figure 2 and Supplementary Table 6). 
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To identify the most robust markers of metastasis, a leave- one-out (LOO) cross-validation procedure [11] 
reduced the initial 200-gene signature to a 58-transcript set comprising sequences that are present in all LOO 
datasets at a threshold of p ≤ 0.01 (Fig. 1). A classifier based on the expression of the 58-transcript set was 
able to correctly discriminate all samples according to patient outcome (≥5-year disease-free versus 
metastasis), with the exception of one case (P598) (Fig. 1, right panel). 
To evaluate the potential of this 58-transcript set to discriminate breast cancer patients according to the time 
required to develop metastasis, we generated a KM survival curve and this analysis showed significant 
discriminating power (p < 0.0001) in stratifying the patient samples according to time to develop metastasis 
(Fig. 2a). For comparison, survival curves were generated based on Her2 and Ki67 expression statuses or the 
tumor histopathological grade, three currently used parameters to infer breast cancer outcome. It is apparent 
that the 58-gene set outperformed Her2 (p = 0.199) and Ki67 (p = 0.115) (Fig. 2b, c, respectively) and was 
comparable to the histopathological grade (p = 0.0082) (Fig. 2d) in discriminating patients according to their 
risk of developing metastasis. ROC curves were constructed to assess the individual potential of each gene 
from the metastasis signature to classify patients according to their disease outcomes. For each gene, the 
AUC was estimated to measure the sensitivity and specificity of the biomarker to correctly select the disease-
free and metastatic cases. The AUC values ranged from 0.933 to 0.807 (Supplementary Table 7), suggesting 
good biomarker performance. 
Biological network analysis 
Enrichment analysis using two methods (IPA and KOBAS) identified pathways that are significantly over-
represented (p <0.05) among the 58-gene metastasis signature (Table 1). These included TRAF6 mediated 
NF-kB activation, p53 pathway, Toll Like Receptor cascades (TLR5, TLR7/8, TLR6/2; TLR3/TLR4; TLR3; 
TLR2, TLR9 and TLR10), TRAF6 mediated induction of NFkB and MAP kinases; Eph-ephrin signaling; 
PECAM1 interactions; HDL-mediated lipid transport; p75NTR signaling complexes; IRAK1 recruitment of 
the IKK complex; WNT5A-dependent internalization of FZD4 and signaling by Rho GTPases (Table 1). 
 
Validation of molecular markers of metastasis in breast cancer 
To document the expression of the genes identified in the metastasis signature in independent datasets, the 
58-gene signature was cross-referenced with the list of genes differentially expressed in metastatic breast 
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cancer studies retrieved from the data collected and processed at the NCBI-GEO database 
(http://www.ncbi.nlm.nih.gov/geo/) originated from ten studies reported in the literature [11, 36-45] . The 
cut-off values for selecting gene lists from each analysis were adjusted between p < 0.001 to p < 0.05 to 
retrieve a comparable number of genes in each analysis. In this meta-analysis, 12 transcripts were found in 
common. From this set, 8 showed the same direction of transcriptional change observed in our study in 50% 
or more of the studies used in the meta-analysis (Table 2). Of note, only the GTSE1 and ZNF664 genes from 
our 58-gene signature showed overlap with the genes present in the commercially available metastasis 
signature MamaPrint® [11] and none of them were found in common with the Oncotype DX qRT-PCR 
based signature [46].  
Additionally, the ability of the 58-gene signature to predict patient outcome was evaluated in different 
publicly available breast cancer datasets [42, 47]. Using the SurvExpress multigene biomarker validation tool 
[33], we found that the metastasis signature was very effective to discriminate patients at higher risk of 
developing metastasis in the breast cancer datasets described by van de Vijver et al. [42] (n = 249, p = 
4.1e−11, HR= 5.2, 95% CI 2.9 − 9.5; Fig. 3a) [41] and by Kao et al. [47] (n = 367, p = 7.9 e−8, HR= 3.6, 95% 
CI 2.2 – 6.0; Fig. 3b). The metastasis signature also stratified these patients according to overall survival (p = 
1.8 e−9, HR= 4.5, 95% CI 2.6 – 7.7 and p = 6.7 e−10, HR= 4.6, 95% CI 2.7 – 7.9, respectively) 
(Supplementary Fig 3a,b). The potential of the 58-metastasis signature to predict disease outcome was 
further corroborated by its ability to discriminate patients according to the overall survival using RNAseq 
gene expression data generated by the TCGA consortium from a cohort of 502 BC patients (p = 3.2 e−9, HR= 
5.2, 95% CI 2.9 – 9.5; Supplementary Figure 3, panel c) [45]. 
We focused on a subset of genes from the metastasis signature (B3GNT7, PPM1D, TNKS2, PHB, and 
GTSE1) due to their importance in cell proliferation or because they are directly or indirectly involved in 
biological processes related to metastasis. Consistent with oligoarray data, all five genes were significantly 
overexpressed (p < 0.05) in tumor samples from patients that developed metastasis relative to those that 
remained disease-free when the same samples (24-samples test set) were evaluated by RT-qPCR 
(Supplementary Fig. 4, left panels). More importantly, similar results were observed in an independent set of 
samples (validation set) comprising 47 primary tumor samples from patients that remained disease free after 
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surgery, and 8 primary tumor samples from patients that developed metastasis (Supplementary Fig. 4, right 
panels). 
The BCL2-associated agonist of cell death (BAD) gene was downregulated in tumors from patients that 
developed metastasis (Supplementary Table 6). BAD protein expression was evaluated in a TMA comprising 
1276 primary BC tissue samples from patients who developed metastasis (432 samples) or remained disease-
free (370 samples) (Table 3). The tumors from patients who developed distant metastasis during the follow-
up period exhibited lower expression levels of BAD (p < 0.0001). Reduced BAD expression was also 
statistically associated with positive lymph node status (p = 0.0035), negative ER (p < 0.0001), negative PR 
(p < 0.0001), negative Her2 (p = 0.0182), more advanced pathological stages (p = 0.0002), and tumor size 
(T3-T4) (p = 0.0002). Interestingly, the percentage of cases with absent/low BAD expression (score 0) 
increased according to the number of lymph nodes involved. No statistically significant association was 
observed between BAD protein expression and age, family history, presence of distant metastasis at 
diagnosis, and histological grade (Table 3). In addition, the survival analysis showed that downregulation of 
BAD in primary tumors was significantly associated with SDFS (p = 0.0001, HR = 1,63; 95% CI 1,23 to 
2,15) and CSS (p < 0.0001, HR = 1,65; 95% CI 1,25 to 2,18) (Fig. 4). However, in the multivariate analyses 
BAD expression was not statistically associated with SDFS or CSS (data not shown). 
 
Discussion  
In this study, a 58-gene expression signature associated with the clinical outcomes of BC in a cohort of 
Brazilian patients was identified, thus revealing new molecular markers with prognostic potential. The cross-
referencing of this 58-gene set with the breast cancer prognosis signatures from 10 studies reported in the 
literature [11, 36–44] revealed 10 genes with concordant gene expression changes in at least one other 
analysis. Despite the discrepancies, this analysis reinforces the prognostic value of some genes, such as 
ITGAV, GTSE1, and AP2B, in breast cancer. Disagreement between gene signatures is frequently observed 
and may originate from individual variations, the molecular and clinical heterogeneity of tumors, the use of 
different platforms, and differences in patient selection, data normalization, methods of analysis, and other 
experimental choices [48]. In this regard, we observed a modest overlap with the genes present in the 
MammaPrint® signature and no overlap with the genes of the Oncotype Dx® signature. 
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The 58-gene metastasis signature was further evaluated in three independent BC patient datasets with follow-
up infor- mation. The metastasis gene set was able to stratify BC metastasis signature for risk stratification 
and highlight the value of this gene set as a resource to select candidates for biomarker development in BC. 
The 58-gene set identified in this study was enriched in molecular pathways that may contribute to the 
metastatic dissemination of breast tumors. Noteworthy, the toll-like receptor (TLR) cascade pathway was 
represented by nine members of the TLR family (TLR5, TLR7/8, TLR6/2; TLR3/TLR4; TLR3; TLR2, TLR9, 
and TLR10). TLRs initiate a series of downstream signaling events that drive cellular responses, including 
the production of cytokines, chemokines, and other inflammatory mediators. In addition to driving 
inflammatory responses, TLRs also regulate cell proliferation and survival, which serves to expand useful 
immune cells and integrate inflammatory responses and tissue repair processes [49]. In colorectal cancer, 
TLR signaling may promote metastasis by activating the expression of integrins and chemokine receptors 
that facilitate tumor cell migration and the colonization of distal sites [50]. Several reports suggest that the 
TLR signaling pathway may play a supporting role in the secretion of pro-inflammatory 
cytokines/chemokines, aggressive tumor behavior (e.g., NF-κB activity), cell proliferation, cell invasion, cell 
migration, and metastasis in breast tumor cells [51]. Our study indicates that augmented TLR signaling is 
also a feature of metastatic breast tumors. 
Genes associated with the p53 pathway were also overrepresented among the metastasis-associated gene set. 
The p53 protein directly controls the transcription of genes that are involved in canonical metastasis 
pathways, including cell adhesion, motility, invasion, EMT, stemness, and ECM interactions [52]. Eph-
ephrin signaling genes were also identified in this signature. This family of molecules is involved in many 
aspects of both normal and carcinogenic developmental processes. In breast cancer, the roles of Eph 
receptors are extremely versatile and multifaceted, as they either promote or suppress tumor functions. The 
tumor-promoting effects seem to prevail [53], which is in agreement with our findings. 
Molecular pathways associated with BC invasiveness have also been identified. TRIP10, also known as 
Cdc42- interacting protein-4 (CIP4), was found upregulated in the tumors from patients who developed 
metastasis. Higher CIP4 levels have been shown to be significantly associated with a greater risk of 
metastatic progression in triple-negative breast cancer patients [54]. In addition to its value as a biomarker 
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for patient outcome, it has been demonstrated that CIP4 localizes to cell invadopodia and positively 
contributes to cell invasion and metastasis in in vivo and in vitro breast cancer models, pointing to the 
functional relevance of this gene for metastatic dissemination in BC [54, 55]. 
B3GNT7, PPM1D, TNKS2, PHB and GTSE1 genes were significantly differentially expressed in the 
independent validation set. These genes were upregulated in the patients that developed metastasis in 
comparison with those that remained disease-free. B3GNT7 and PPM1D genes were previously associated 
with poor outcome of breast cancer patients [56]; however the value of TNKS2, PHB, and GTSE1 genes as 
prognostic markers is currently unknown. B3GNT7 encodes an enzyme that is involved in a broad variety of 
biological functions that are mainly related to cell-cell communication [57], differentiation [58], and certain 
infectious diseases [59] besides promoting cell motility and invasion in vitro [60]. The increased expression 
of B3GNT7 in metastatic cases, compared to cases without metastasis, indicates that this gene may be an 
important prognostic marker in breast cancer.  
PPM1D is a hotspot for gene amplification in breast cancer [61] and has been detected in both breast cancer 
cell lines and primary breast tumors, which suggests its involvement in cancer development [56, 62]. 
PPM1D is involved in the regulation of several essential signaling pathways that are implicated in BC 
pathogenesis, such as the inhibition of tumor suppressor activities of TP53 [63], p16INK4A, and p19ARF 
[64] and the activation of oncogenes, such as RAS, MYC, and NEU, thus promoting cellular transformation 
[65, 66]. In addition, PPM1D targets other key stress response kinases, such as ATM, CHK1, CHK2, and 
UNG2, which function in the DNA damage response and repair [63, 67]. These findings indicate that 
PPM1D is involved in the regulation of several essential signaling pathways that are implicated in breast 
cancer pathogenesis, and, therefore, it could be considered as a potential therapeutic target in BC patients. 
TNKS2 (codified enzyme tankyrase, TRF1-interacting an- kyrin-related ADP-ribose polymerase 2) positively 
regulates telomere length, and its expression has been detected in meningiomas and breast cancer [68]. The 
tumor suppressor gene PHB (prohibitin) encodes an anti-proliferative protein that functions by interacting 
with the Rb protein and its family members. Their putative association with the immunoglobulin (Ig)M 
receptor and estrogen receptor has suggested to have a possible role in cellular signaling, whereas the 
binding of prohibitin to E2F proteins has been taken as an indication of a possible role of PHB in 
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transcriptional regulation during the cell cycle [69]. PHB is overexpressed in several carcinomas, and its role 
in tumorigenesis has been associated with the modulation of cell cycle control via Ras-Raf signaling, cell 
migration, mitochondrial physiology, and apoptosis [70, 71]. In this study, TNKS2 and PHB were 
upregulated in cases that presented metastasis in comparison to cases without metastasis in both the test and 
validation sets. Based on these results, we suggest that these genes may be potential prognostic markers of 
breast cancer. 
GTSE1, which is present in the 58-gene metastasis signature, was also differentially expressed in patients 
with metastatic breast cancer, with the same signal direction as the TGCA analysis (2015). This gene (G2 
and S phase- expressed-1) plays a role in the G2 phase of the mitotic cell cycle. Its protein is co-localized 
with tubulin, suggesting that GTSE1 is associated with microtubules [72]. A physical interaction occurs 
between the C-terminal region of GTSE1 and the C-terminal regulatory domain of p53, which is necessary 
and sufficient to downregulate p53 activity. After DNA damage, GTSE1 could play a dual role during the G2 
checkpoint, promoting a delay of the G2 to M transition and, at the same time, protecting these cells from 
p53-dependent apoptosis [73]. In one study, GTSE1 was found to be highly expressed in oral tongue 
squamous cell carcinoma samples and significantly associated with patients presenting lymph node 
metastasis [74]. To our knowledge, there are no previous studies associating the clinico-pathological 
significance of GTSE1 in patients with breast carcinoma. 
We observed reduced expression of BAD (BCL2-associated agonist of cell death) in the tumors of patients 
that developed metastasis compared to patients that remained metastasis-free. We found significant 
associations between BAD downregulation and occurrence of distant metastasis during the ≥ 5-year follow-
up period (p<0.0001), positive nodal status (p=0.0035), negative ER (p<0.0001), negative PGR (p<0.0001), 
negative Her2 (p=0.0182) and tumor size (T3-T4) (p=0.0002). In addition, the survival analysis showed that 
reduced BAD expression was statistically associated with shorter systemic disease free-survival (p=0.001) 
and cancer specific survival (p<0.001). Cekanova et al. [75] suggest that, in addition to the effect on 
apoptosis, BAD conveys anti-metastatic effects and is a valuable prognostic marker in breast cancer. In line 
with this study, the gene and protein expression levels that were downregulated in our 58-gene set and 
protein analysis suggest that expression level of BAD is a clinically relevant prognostic marker in breast 
carcinomas.  
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In conclusion, in this study we identified a 58-gene expression signature able to distinguish patients 
according to their risk of developing metastasis or overall survival more effectively than clinico-pathological 
factors currently used for BC prognosis. This metastasis signature showed prognostic value in independent 
BC patient datasets. A subset of these genes was validated by transcript or protein expression analyses in an 
independent panel of samples, and the results highlighted candidates with the potential to stratify patients 
according to their risk of developing distant metastasis after diagnosis. Further studies with extended panels 
of patient samples are warranted to validate the clinical relevance of the novel biomarker candidates 
identified here. 
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Legends to Figures  
 
Fig 1 - A metastasis-associated gene expression signature. Fifty-eight genes and partial transcripts (ESTs) 
differentially expressed (p ≤ 0.01) between invasive ductal breast tumor samples from patients with evidence 
of metastasis (n=9; full circles) and samples from patients that remain disease-free after at least 5-years 
follow-up (n=15; open circles) were identified following leave-one-out resampling (see Materials and 
methods for details). The genes (columns) are ordered by their correlation coefficient (signal-to-noise ratio) 
with the two patient outcome groups. Samples (rows) are ordered by their correlation to the metastasis 
profile, which is shown in the right panel. Expression level of each gene is represented by the number of 
standard deviations above (red) or below (green) the average value for that gene across all samples. Patients 
that remained metastasis-free have a correlation lower than 0.1 with the metastasis profile (dashed line in the 
right panel). 
 
Fig 2 - Kaplan-Meier estimates of metastasis occurrence in patients with invasive ductal breast cancer based 
on the 58-gene metastasis signature(a), expression status of the Her2 receptor (b) or the Ki67 proliferation 
marker (c), and the histopathological grade (d). 
 
Fig 3 - Kaplan-Meier estimates of metastasis occurrence in patients with invasive breast cancer based on 
public available data using the metastasis signature to generate risk scores (see Material and Methods for 
details). a. Two hundred ninety-four samples of primary breast carcinoma (data from [42]); b. Three hundred 
sixty-seven samples of breast carcinoma (data from [47]). The Log-rank test was used to ascertain the 
statistical difference between the survival curves.  
 
Fig 4 – Systemic disease-free survival (SDFS, a) and cancer specific KM survival (CSS, b) curves according 
to BAD protein status in breast tumor samples. p = 0.0001 for SDFS and p < 0.0001 for CSS were 
determined by log-rank test. 
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Table 1 – Gene enrichment analysis using the 58-gene signature performed with Ingenuity Pathway Analysis 
(IPA) and KOBAS 2.0 tools. 
 
Pathways Database ID P-Value 
RIP-mediated NFkB activation via ZBP1 IPA,Reactome REACT_118563 0.002 
TRAF6 mediated NF-kB activation IPA,Reactome REACT_24969 0.002 
ZBP1(DAI) mediated induction of type I IFNs IPA,Reactome REACT_118764 0.003 
TAK1 activates NFkB by phosphorylation of 
IKKs  
IPA,Reactome REACT_21281 0.003 
p53 pathway IPA,Reactome REACT_121025 0.004 
Nef Mediated CD8 Down-regulation IPA,PANTHER P00059 0.006 
MyD88 cascade initiated on plasma membrane IPA,Reactome REACT_121175 0.009 
Toll Like Receptor 5 (TLR5) Cascade IPA,Reactome REACT_118823 0.015 
Toll Like Receptor 10 (TLR10) Cascade IPA,KEGG hsa05222 0.016 
TRAF6 mediated induction of NFkB and 
MAP kinases  
IPA,Reactome REACT_25359 0.020 
p53 pathway feedback loops 2 IPA,Reactome REACT_11200 0.021 
MyD88 dependent cascade initiated on 
endosome 
IPA,Reactome REACT_27215 0.022 
Toll Like Receptor 7/8 (TLR7/8) Cascade IPA,Reactome REACT_9061 0.022 
Toll Like Receptor 9 (TLR9) Cascade IPA,Reactome REACT_9027 0.022 
Nef Mediated CD4 Down-regulation IPA,Reactome REACT_25024 0.023 
EPH-Ephrin signaling IPA,PANTHER P04398 0.023 
Toll Like Receptor TLR6:TLR2 Cascade IPA,Reactome REACT_25222 0.024 
Toll Like Receptor 2 (TLR2) Cascade IPA,Reactome REACT_9020 0.024 
Toll Like Receptor 3 (TLR3) Cascade IPA,Reactome REACT_9047 0.025 
TRIF-mediated TLR3/TLR4 signaling IPA,Reactome REACT_11166 0.026 
PECAM1 interactions IPA,Reactome REACT_6788 0.027 
HDL-mediated lipid transport IPA,Reactome REACT_228170 0.027 
p75NTR recruits signalling complexes IPA,Reactome REACT_8006 0.027 
NF-kB is activated and signals survival IPA,Reactome REACT_8005 0.028 
Activated TLR4 signalling IPA,Reactome REACT_7980 0.028 
IRAK1 recruits IKK complex IPA,Reactome REACT_6783 0.030 
WNT5A-dependent internalization of FZD4 IPA,Reactome REACT_6809 0.030 
Rho GTPase cycle IPA,Reactome REACT_25281 0.030 
Signaling by Rho GTPases IPA,Reactome REACT_12519 0.031 
p75NTR signals via NF-kB IPA,Reactome REACT_13621 0.034 
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Table 2 – The 58-gene metastasis signature was cross-referenced with lists of genes differentially expressed 
in metastatic breast cancer, retrieved from the data collected and processed at the NCBI-GEO database 
(http://www.ncbi.nlm.nih.gov/geo/) and originated from ten studies reported in the literature. Twelve genes 
that appeared in three or more studies were selected. Of these genes, 8 had the same signal direction for the 
fold change in more than 50% of studies in which expression values were measured. For each gene, 
expression values are shown and refer to log2 ratios between metastatic and non-metastatic breast tumors. 
  
 
Gene Description This study 
aTCGA  
bvan't 
Veer 
et al. 
cvan de 
Vijver et 
al. 
dDesmedt 
et al. 
eMinn 
et al. 
fZhao 
et al. 
gKarlsson 
et al. 
hWang 
et al. 
iSørlie 
et al. 
jMolly 
et al. 
k
Jézéquel 
et al. 
GTSE1 G-2 and S-
phase 
expressed 1 
 1.2 2.9  0.4 0.3 0.3    -0.1  -0.3  -0.7  
AP2B1 adaptor-
related 
protein 
complex 2, 
beta 1 subunit 
-1.4 0.06 -0.6   -0.2   -0.2 -0.2  -0.1  0.2  
ANGPTL1 angiopoietin-
like 1 
-1.5 -2.3  -0.5    0.4  0.3  0.5  
IKBKB inhibitor of 
kappa light 
polypeptide 
gene enhancer 
in B-cells 
-1.3 0.3    -0.3  0.9 -0.1 0.1   0.3  
FXYD1 FXYD 
domain-
containing ion 
transport 
regulator 1 
-1.0 -3.4   -0.2    -0.1 -0.1   0.1 0
.4 
SND1 Staphylococc
al nuclease 
and tudor 
domain 
containing 1 
0.4 0.07    0.2    -0.09 -0.1 0
.1 
ZNF664 zinc finger 
protein 664 
0.5 0.07 0.6       0.1   
ITGAV integrin, alpha 
V 
1.0 -0.06     0.5 0.5  0.3  0.4  
NETO2 neuropilin 
(NRP) and 
tolloid (TLL)-
like 2 
1.2 0.8   0.3   -1.2 -0.8  -0.2 -0.5  
PIP4K2A phosphatidyli
nositol-5-
phosphate 4-
kinase, type 
II, alpha 
0.5 0.3   -0.1  0.7      
EXDL2 exonuclease 
3'-5' domain-
like 2 
0.4   -0.3     -0.06 0.1  0.1  
FKBP1B FK506 
binding 
protein 1B 
1.6 -0.2   -0.1     -0.3 -0.4  
aTCGA (2012); bNature (2002) 415:484; cN Engl J Med. (2002) 347:1999; dClin Cancer Res. (2007) 13:3207; eNature (2005) 436:518; fMol Biol Cell. 
(2004) 15:2523; gBMC Cancer (2008) 8:254; hBreast Cancer Res (2011) 13(5):R92; iBMC Genomics (2006) 7:127; jPLoS One (2012) 7(2):e32426; 
kBreast Cancer Res Treat (2009) 116(3):509-20. 
 
 
 
 
 
  
Table 3 – BAD protein expression in breast tumor samples detected by immunohistochemistry in tissue 
microarray and its association with clinical-pathological variables. Significant associations are in bold. 
 
Variables N 
BAD expression score (%)  
p-value negative positive 
Age (years)    0.2440 
 <50 351 78 (22) 273 (78) 
 ≥50 557 106 (19) 451 (81) 
 908    
Familial history    0.3757 
 No 676 142 (21) 534 (79)  
 Yes 183 33 (18) 150 (82)  
 859    
T    0.0002 
 T1 76 13 (17) 63 (83)  
 T2 384 54 (14) 330 (86)  
 T3 128 33 (26) 95 (74)  
 T4 277 74 (27) 203 (73)  
 865    
N    0.0035 
 N0 269 38 (14) 231 (86)  
 N1 265 54 (20) 211 (80)  
 N2 210 47 (22) 163 (78)  
 N3 141 41 (29) 100 (71)  
 885    
M    0.8366 
 Negative 816 167 (20) 649 (80)  
 Positive 72 14 (19) 58 (81)  
 888    
Pathological Stage    0.0002 
I 41 7 (17) 34 (83)  
II 359 49 (14) 310 (86)  
III 422 112 (27) 310 (74)  
IV 72 14 (19) 58 (81)  
     
Histological grade    0.6835 
 G1 120 21 (18) 99 (82)  
 G2 532 112 (21) 420 (79)  
 G3 259 53 (20) 206 (80)  
 911    
ER    <0.0001 
Negative 279 86 (31) 193 (69)  
Positive 587 83 (14) 504 (86)  
 866    
PR    <0.0001 
Negative 453 118 (26) 335 (74)  
Positive 384 43 (11) 341 (88)  
 837    
Her2    0.0182 
Negative 654 147 (22) 507 (78)  
Positive 117 15 (13) 102 (87)  
 771    
Distant metastasis    <0.0001 
No 432 65 (15) 367 (85)  
Yes 370 97 (26) 273 (74)   
 802    
T: Tumor; N: Nodes; M: Metastasis; ER: estrogen receptor alpha; PR: progesterone receptor; Her2: human epidermal 
growth factor receptor 2.  
 
